However, there are several concerns about the SGLT2 inhibitors’ effects on bone metabolism regarding the following: (1) stimulation of parathyroid hormone (PTH) and fibroblast growth factor 23 by the increased serum phosphate levels via tubular reabsorption in phosphate, (2) weight loss, and (3) volumetric depletion and fall risk (e.g., orthostatic hypotension and postural dizziness) [15]. The gene discussed is PTH; the disease is orthostatic hypotension.